CN107744583B - Traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway anaphylactic reaction, and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway anaphylactic reaction, and preparation method and application thereof Download PDFInfo
- Publication number
- CN107744583B CN107744583B CN201711013148.9A CN201711013148A CN107744583B CN 107744583 B CN107744583 B CN 107744583B CN 201711013148 A CN201711013148 A CN 201711013148A CN 107744583 B CN107744583 B CN 107744583B
- Authority
- CN
- China
- Prior art keywords
- parts
- upper airway
- chinese medicine
- traditional chinese
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
Abstract
The traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway anaphylactic reaction, the preparation method and the application thereof are as follows, the raw material medicines are in parts by weight: 5-7 parts of platycodon grandiflorum, 8-10 parts of perilla leaves, 9-11 parts of mulberry leaves, 5-7 parts of honey-fried licorice roots, 3-5 parts of gardenia, 9-11 parts of fermented soybean, 13-17 parts of radish seeds, 5-7 parts of cassia seeds, 5-7 parts of angelica dahurica, 5-7 parts of polygonatum odoratum, 5-7 parts of ginger, 9-11 parts of Chinese dates, 5-7 parts of mint and 8-10 parts of Chinese olive. The composition form is as follows: freeze drying herba Menthae to obtain powder, extracting the rest materials with boiling water to obtain concentrated solution, and spray drying to obtain powder. The whole formula is prepared by combining the characteristics of upper airway throat diseases on the basis of the classical name formula, and clinical tests prove that the traditional Chinese medicine composition can effectively control the upper airway inflammation and anaphylactic reaction and has exact curative effect on chronic cough caused by acute and chronic pharyngolaryngitis, chronic tracheitis, chronic bronchitis and the like.
Description
Technical Field
The invention relates to a composition, in particular to a traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway anaphylactic reaction. The invention also relates to a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparing a medicine for relieving upper airway inflammation and controlling upper airway anaphylactic reaction.
Background
In recent years, the number of people suffering from chronic respiratory diseases has been on the rise due to the gradual deterioration of air quality, and the common causes of the chronic respiratory diseases are upper airway inflammation and the high sensitivity of the upper airway for a long time. The most prominent manifestation of upper airway inflammation is chronic cough, which has complex pathogenesis and long duration of disease course and seriously affects daily work and life.
The traditional Chinese medicine treatment has unique advantages in this respect. Based on the guiding theory that the five zang-organs and six fu-organs all cause cough and the lung is not independent, the traditional Chinese medicine deeply studies ancient training, combines the modern clinical characteristics and distinguishes the prescription, and has better curative effects on relieving the inflammation of the upper airway and controlling the allergic reaction of the upper airway.
The effective rate of the traditional Chinese medicine composition is 10g, the effective rate of the traditional Chinese medicine composition is 100 g, the effective rate of the traditional Chinese medicine composition is 10g, the effective rate of the traditional Chinese medicine composition is 100 g, the effective rate of the traditional Chinese medicine composition is 10g, the effective rate of the traditional Chinese medicine composition is 10g, the traditional Chinese medicine composition is 100 g, the traditional Chinese medicine composition is 10g, the radix scutellariae is 10g, the traditional Chinese medicine composition is 5g, the traditional Chinese medicine composition is 2015 5g, the honey-prepared by 10g, the traditional Chinese medicine composition is 10g, the radix peucedani is 10g, the bombycine is 0, the bombycine l is 0, the nasal itching, the nasal symptoms and the nasal symptoms are accompanied by the clinical test composition, the nasal itching, the nasal symptoms, the cough is the effective rate is the cough is the clear nasal itching, the clear nasal obstruction is 3g, the clear nasal obstruction of the clear nasal
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway anaphylactic reaction. Aiming at the upper airway inflammation and the airway anaphylactic reaction, the invention adopts a method of clearing heat and relieving sore throat, nourishing yin and clearing hollow viscera, and provides a new idea for establishing a treatment system for relieving the upper airway inflammation and controlling the upper airway anaphylactic reaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparing a medicine for relieving upper airway inflammation and controlling upper airway anaphylactic reaction.
The technical scheme for completing the first invention task of the application is that the traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway anaphylactic reaction is characterized in that the traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 5-7 parts of platycodon grandiflorum, 8-10 parts of perilla leaves, 9-11 parts of mulberry leaves, 5-7 parts of honey-fried licorice roots, 3-5 parts of gardenia, 9-11 parts of fermented soybean, 13-17 parts of radish seeds, 5-7 parts of cassia seeds, 5-7 parts of angelica dahurica, 5-7 parts of polygonatum odoratum, 5-7 parts of ginger, 9-11 parts of Chinese dates, 5-7 parts of mint and 8-10 parts of Chinese olive.
The applicant recommends that the optimal proportion of the raw material medicines of the traditional Chinese medicine composition in parts by weight is as follows: 6 parts of platycodon grandiflorum, 9 parts of perilla leaves, 10 parts of mulberry leaves, 6 parts of honey-fried licorice roots, 4 parts of gardenia, 10 parts of fermented soybeans, 15 parts of radish seeds, 6 parts of cassia seeds, 6 parts of angelica dahurica, 6 parts of radix polygonati officinalis, 6 parts of ginger, 10 parts of Chinese dates, 6 parts of mint and 9 parts of Chinese olive.
Namely, the formula of the raw material medicaments for each treatment medication is as follows: 6g of platycodon grandiflorum, 9g of perilla leaf, 10g of mulberry leaf, 6g of honey-fried licorice root, 4g of cape jasmine fruit, 10g of fermented soybean, 15g of radish seed, 6g of cassia seed, 6g of angelica dahurica, 6g of polygonatum odoratum, 6g of ginger, 10g of Chinese date, 6g of mint and 9g of Chinese olive.
The traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway anaphylactic reaction comprises the following components in form: the herba Menthae is frozen powder, and the other raw materials are extract concentrated solution obtained by boiling extraction, and then spray drying to obtain powder.
The technical scheme for completing the second invention task of the present application is that the preparation method of the traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway anaphylactic reaction is characterized by comprising the following steps:
⑴, weighing the raw materials;
⑵, boiling and extracting the raw materials except herba Menthae;
⑶ concentrating the extract obtained by boiling;
⑷, spray drying the concentrated solution obtained in step ⑶ to obtain powder;
⑸ pulverizing herba Menthae by freeze drying;
⑹ mixing the freeze dried powder of herba Menthae with the powder of other raw materials obtained in step ⑷ to obtain the final product.
The optimization operation method of the above step ⑵ is:
⑵ -1, primary extraction:
boiling and extracting;
the material-liquid ratio is 1: 10;
sieving for 60min, and discharging;
⑵ -2, secondary extraction, namely boiling extraction, wherein the ratio of material to liquid is 1: 5;
the time is 30min, and the materials are sieved and discharged.
The optimization operation method of the above step ⑶ is:
⑶ -1 centrifugal, straight tube centrifuge, 14000rpm
⑶ -2, concentrating by an RO membrane.
The technical scheme for completing the third invention task of the present application is the application of the traditional Chinese medicine composition for relieving the upper airway inflammation and controlling the upper airway anaphylactic reaction in the preparation of the medicine for relieving the upper airway inflammation and controlling the upper airway anaphylactic reaction.
The inventors have conducted a systematic clinical study of the compositions of the present protocol.
1. The data source:
120 cases of cough patients with upper airway inflammation who are treated by Nanjing Mingji hospitals from 3 to 2016 are selected as study objects and divided into 60 cases in a treatment group and 60 cases in a control group. All patients met the diagnostic criteria.
2. Selection criteria for cases:
2.1 diagnostic criteria:
2.1.1 Western diagnostic standards:
according to the standard reference of 'cough diagnosis and treatment guideline' (draft) and 'clinical diagnosis and treatment of chronic cough' formulated by the respiratory disease division asthma school of the Chinese medical society in 2005.
2.1.2 Chinese medicine diagnosis standard:
refer to the Chinese medical syndrome diagnostic standard of "advanced medical colleges and universities Chinese medicine internal science textbook" and "advanced education Chinese medicine diagnostics textbook" in the new century.
2.2 inclusion criteria:
(1) patients who meet the diagnostic criteria.
(2) Chronic cough for 4 weeks or more.
2.3 exclusion criteria:
(1) can be used for treating pulmonary organic diseases such as pneumonia, endobronchial tuberculosis, pulmonary interstitial fibrosis, emphysema, pulmonary heart disease, and lung cancer.
(2) Severe nausea, vomiting, diarrhea, severe infection and drug allergy.
2.4 rejection criteria:
(1) the patients who can not be treated normally after the treatment are grouped;
(2) during the administration period, the patient takes other medicines simultaneously, which leads to the case that the curative effect can not be judged;
(3) the pathology of taking the medicine cannot be adhered to for reasons;
(4) cases without any recordable evaluation record after taking the drug;
(5) cases of natural shedding;
2.5 grouping and dosing:
120 patients were randomized into treatment and control groups using a random number table.
(1) Treatment groups: the self-prepared heat-clearing throat-benefiting, yin-nourishing and bowel-relaxing medicine comprises the following components: 6g of platycodon grandiflorum, 9g of perilla leaf, 10g of mulberry leaf, 6g of honey-fried licorice root, 4g of cape jasmine fruit, 10g of fermented soybean, 15g of radish seed, 6g of cassia seed, 6g of angelica dahurica, 6g of polygonatum odoratum, 6g of ginger, 10g of Chinese date, 6g of mint and 9g of Chinese olive
Decocting with water, one dose per day, and warm-taking 2-3 times a day, 7 days as a treatment course, recording and observing treatment results after the treatment course, and treating for 4 treatment courses.
(2) Control group: the composition is orally taken 3 times a day, 1 bottle is taken each time, 7 days are a treatment course, and the results are recorded in time after the treatment course is finished, so that 4 treatment courses are total.
(3) Drug source and preservation
The medicine is prepared from Chinese medicinal decoction pieces or Chinese patent medicine from Mingji Hospital of subsidiary teaching Hospital of Nanjing Chinese medicinal university, and is stored and managed by a special person for research and medication, and stored in dry and shady places.
2.6 observation indexes:
the conventional indexes are as follows: body temperature, pulse, blood pressure, respiration and possible adverse reactions;
observation of symptoms and curative effects;
the observation method refers to the Chinese national standard of the Chinese medicine industry standard of the people's republic of China-the diagnosis and treatment effect standard of the symptom and condition of traditional Chinese medicine.
2.7 the therapeutic effect judgment standard of syndrome:
the method for evaluating the curative effect by referring to the clinical research guiding principle of the new Chinese medicine (Beijing: Chinese pharmaceutical science and technology publisher, 2002) comprises the following steps of calculating a formula (nimodipine method) that a curative effect index (n) ═ integration before treatment-integration after treatment/integration before treatment × 100%
(1) Clinical cure: clinical symptoms and physical signs disappear or basically disappear, and n percent is more than or equal to 95 percent;
(2) the effect is shown: clinical symptoms and physical signs are obviously improved, and n percent is more than or equal to 70 percent and less than 95 percent;
(3) the method has the following advantages: the clinical symptoms and physical signs are improved, and n percent is more than or equal to 30 percent and less than 70 percent;
(4) and (4) invalidation: clinical symptoms and signs are not obviously improved or even aggravated, and n% is less than 30%.
The evaluation standard of curative effect is as follows:
refer to the standard of curative effect of cough in the standard of Chinese medicine industry of people's republic of China, "standard of curative effect of diagnosis of internal diseases and symptoms of traditional Chinese medicine".
And (3) curing: cough and accompanying symptoms disappear, auscultation respiratory sounds are clear, dry rales disappear, and if fever occurs, the body temperature is reduced to normal;
improvement: cough and accompanying symptoms are relieved, breath sound is clear, and sputum volume is reduced;
the disease is not cured: the cough symptoms and signs are not improved or aggravated.
2.8 statistical analysis:
the research content is summarized and designed into a clinical observation table, all indexes of the patient before and after treatment are faithfully recorded, and statistical analysis is carried out by adopting medical statistical software SPSS 21.0. Normal distribution data are calculated by mean standard deviation and expressed by mean +/-S, and count data are compared by adopting pairing T test and a four-grid table exact probability method. P < 0.01 is a very significant difference, P <0.05 is a significant difference, and P > 0.05 is no significant difference.
3, results:
3.1 comparison of symptom sign integral before and after treatment:
comparison of integral signs before and after treatment (mean. + -. standard deviation)
3.2 curative effect judgment:
comparison of therapeutic effects after different treatment periods
Using four-grid tables X2Tests were performed to analyze the difference in efficacy between the treatment group and the control group at different times.
3.2.1 comparison of efficacy after 1 week of treatment:
group therapeutic effect cross tabulation
X242.553, P is 0.00 < 0.01, the difference of the total effective rate of the treatment group and the control group after one week has statistical significance, the effective rate of the treatment group is 58.3% higher than 3.3% of the control group, and the treatment effect of the treatment group is better than that of the control group.
3.2.2 comparison of efficacy after 2 weeks of treatment:
group therapeutic effect cross tabulation
X235.307, P is 0.00 < 0.01, the difference of the total effective rate between the treatment group and the control group has statistical significance, the effective rate of the treatment group is 61.4% which is more than 8.6% of the control group, and the treatment effect of the treatment group is obviously better than that of the control group.
3.2.3 comparison of efficacy at 3 weeks of treatment:
group therapeutic effect cross tabulation
X244.958, P0.00 < 0.01, ZhiThe difference of the total effective rates of the treatment group and the control group has statistical significance, the effective rate of the treatment group is 64.0 percent and is more than 3.5 percent of that of the control group, and the treatment effect of the treatment group is obviously better than that of the control group.
3.2.4 treatment 4 weeks efficacy comparison:
group therapeutic effect cross tabulation
X237.726, P is 0.00 < 0.01, the difference of the total effective rate between the treatment group and the control group has statistical significance, the effective rate of the treatment group is 63.0 percent which is more than 5.6 percent of the control group, and the treatment effect of the treatment group is obviously better than that of the control group.
4. As a result:
120 patients who were enrolled in accordance with the standard were randomly divided into a treatment group and a control group, 20 patients were dropped and rejected in the actual study, and the scores before and after treatment of the patients who were finally enrolled in the study statistics, 46 patients in the treatment group and 54 patients in the control group were statistically analyzed. The treatment course is 7 days, the treatment course is 4, and after each treatment course is finished, the treatment effects of the two groups of patients are compared front and back respectively. After one week of treatment, the total effective rate of the treatment group is 58.3%, the total effective rate of the control group is 3.3%, the difference of the total effective rates of the treatment group and the control group has statistical significance (P is less than 0.01), and the treatment effect of the treatment group is obviously better than that of the control group; after two weeks of treatment, the total effective rate of the treatment group is 61.4%, the total effective rate of the control group is 8.6%, the difference of the total effective rates of the treatment group and the control group has statistical significance (P is less than 0.01), and the treatment effect of the treatment group is obviously better than that of the control group; after three weeks of treatment, the total effective rate of the treatment group is 64.0 percent, the control group is 3.5 percent, the difference of the total effective rates of the treatment group and the control group has statistical significance (P is less than 0.01), and the treatment effect of the treatment group is obviously better than that of the control group; after four weeks of treatment, the total effective rate of the treatment group is 63.0%, the total effective rate of the control group is 5.6%, the difference of the total effective rates of the treatment group and the control group has statistical significance (P is less than 0.01), and the treatment effect of the treatment group is obviously better than that of the control group. From the statistical data of the four treatment effects, the treatment effect of the treatment group is obviously better than that of the control group, the treatment effect of the treatment group is generally in an increasing improvement trend, and the treatment effect of the control group is not ideal and is in a low-level unstable state. The effect of the treatment group is always obviously better than that of the control group in terms of the recent symptom improvement and the long-term curative effect.
The whole formula is drawn up by Zhongchun Xiang professor of Nanjing university of traditional Chinese medicine on the basis of the classical famous prescription of Shengzhang Zhongjing of medicine in combination with the characteristics of upper airway throat diseases of contemporary people, and strict clinical tests prove that the curative effect is exact. The observation of 120 cases of patients with upper airway diseases shows that the formula can effectively control the upper airway inflammation and anaphylactic reaction, and has exact curative effect on chronic cough caused by acute and chronic pharyngolaryngitis, chronic tracheitis, chronic bronchitis and the like. The whole formula consists of products used as both medicine and food, is a pure natural food with the function of medicine, has mild function and no obvious toxic or side effect, and is suitable for being taken for a long time. Early animal and clinical experimental research shows that the difference of treatment course between the water decoction mode and the extract spray powder preparation mode of the formula has no statistical significance, and the prepared powder is convenient for long-time administration, so that the prepared powder is convenient for storage and taking with water.
The water decoction mode of the prescription of the invention is the same as the taking treatment effect of the extract spray pulverization mode.
In the formula, the platycodon root and the honey-fried licorice root are platycodon root soup from Shanghai treatise of classic traditional Chinese medical science, are used for treating sore throat, have the effects of dispelling wind, clearing heat and relieving sore throat, are matched with the mulberry leaf and the mint, have better effects of cooling, ventilating the lung and relieving sore throat, and are matched with the purple perilla, the angelica dahurica and the fermented soya bean, which are pungent and warm in nature, and can strengthen the effect of relieving exterior syndrome and relieving sore throat; for a long time, pathogenic factors are stagnated for heat, and the pathogenic factors are mostly transformed into heat, are homologous to the gardenia and fermented soybean soup in Shang Han Lun, can clear heat and promote qi circulation, and are effective prescriptions for removing stagnated heat between chest and diaphragm; yuzhu is sweet, cool, main and moist in flavor, and is especially suitable for those with throat discomfort and yin qi impairment due to matching with Xie and Qing Guo. The lung is exteriorly and interiorly related to the large intestine, the lung meridian has a long-lasting heat accumulation, the lung descends to the stagnant force, the fire-qi descends to expel, the intestine has dryness-heat and qi movement
Radish seed for food stagnationThe cassia seed can smooth the large intestine qi. Ginger and jujube look flat, and have the effects of regulating spleen and stomach, supporting healthy qi, and preventing stomach from being injured by cold drugs. The compatibility of the prescription can play the role of dispersing upper energizer, smoothing throat and protecting airway. Has good health care and rehabilitation effects on chronic pharyngitis, chronic tracheitis, PM2.5, pharyngalgia, pharynx itch, long-term chronic cough and the like caused by airway hyperanaphylaxis after smoking.
Detailed Description
The preparation method comprises the following steps of weighing ⑴ raw materials respectively, ⑵ raw materials except mint, boiling and extracting for ⑵ -1, boiling and extracting for once, mixing the raw materials with water at a ratio of 1: 10, sieving and discharging for 60min, ⑵ -2, boiling and extracting for a second time at a ratio of 1: 5, time 30min, sieving and discharging for 12-3, mixing the obtained concentrated extract with water at a ratio of 1402-1401, RO 2, 150-5, and concentrating by a centrifugal centrifuge at a ratio of ⑶, and concentrating by a straight tube centrifuge at a speed of ⑶ - ⑶, and mixing the obtained concentrated extract with freeze-drying powder of ⑶, ⑶ -6-7.
Example 2, which is essentially the same as example 1, but the formulation of the drug substance for each therapeutic use is: 5g of platycodon grandiflorum, 8g of perilla leaf, 9g of mulberry leaf, 5g of honey-fried licorice root, 3g of cape jasmine fruit, 9g of fermented soybean, 13g of radish seed, 5g of cassia seed, 5g of angelica dahurica, 5g of radix polygonati officinalis, 5g of ginger, 9g of Chinese date, 5g of mint and 8g of Chinese olive.
Example 3, which is basically the same as example 1, but the raw material formula of each therapeutic drug is as follows: 7g of platycodon grandiflorum, 10g of perilla leaf, 11g of mulberry leaf, 7g of honey-fried licorice root, 5g of cape jasmine fruit, 11g of fermented soybean, 17g of radish seed, 7g of cassia seed, 7g of angelica dahurica, 7g of polygonatum odoratum, 7g of ginger, 11g of Chinese date, 7g of mint and 10g of Chinese olive.
Example 4, which is basically the same as example 1, but the raw material formulation of each therapeutic drug is as follows: 5g of platycodon grandiflorum, 10g of perilla leaf, 9g of mulberry leaf, 7g of honey-fried licorice root, 3g of cape jasmine fruit, 11g of fermented soybean, 13g of radish seed, 7g of cassia seed, 5g of angelica dahurica, 7g of polygonatum odoratum, 5g of ginger, 11g of Chinese date, 5g of mint and 10g of Chinese olive.
Example 5, which is basically the same as example 1, but the raw material formulation of each therapeutic drug is as follows: 7g of platycodon grandiflorum, 8g of perilla leaf, 11g of mulberry leaf, 5g of honey-fried licorice root, 5g of cape jasmine fruit, 9g of fermented soybean, 17g of radish seed, 5g of cassia seed, 7g of angelica dahurica, 5g of radix polygonati officinalis, 7g of ginger, 9g of Chinese date, 7g of mint and 8g of Chinese olive.
Example 6, which is essentially the same as example 1, but the raw material formulation of each therapeutic administration is: 7g of platycodon grandiflorum, 10g of perilla leaf, 11g of mulberry leaf, 7g of honey-fried licorice root, 4g of cape jasmine fruit, 10g of fermented soybean, 15g of radish seed, 6g of cassia seed, 6g of angelica dahurica, 6g of polygonatum odoratum, 6g of ginger, 10g of Chinese date, 6g of mint and 9g of Chinese olive.
Claims (7)
1. A traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway anaphylactic reaction is characterized in that the traditional Chinese medicine composition comprises the following raw material medicines in parts by weight: 5-7 parts of platycodon grandiflorum, 8-10 parts of perilla leaves, 9-11 parts of mulberry leaves, 5-7 parts of honey-fried licorice roots, 3-5 parts of gardenia, 9-11 parts of fermented soybean, 13-17 parts of radish seeds, 5-7 parts of cassia seeds, 5-7 parts of angelica dahurica, 5-7 parts of polygonatum odoratum, 5-7 parts of ginger, 9-11 parts of Chinese dates, 5-7 parts of mint and 8-10 parts of Chinese olive.
2. The traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway allergic reaction according to claim 1, which is characterized by comprising the following raw material medicines in parts by weight: 6 parts of platycodon grandiflorum, 9 parts of perilla leaves, 10 parts of mulberry leaves, 6 parts of honey-fried licorice roots, 4 parts of gardenia, 10 parts of fermented soybeans, 15 parts of radish seeds, 6 parts of cassia seeds, 6 parts of angelica dahurica, 6 parts of radix polygonati officinalis, 6 parts of ginger, 10 parts of Chinese dates, 6 parts of mint and 9 parts of Chinese olive.
3. The traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway allergic reaction according to claim 1 or 2, which is prepared from the following components in percentage by weight: the herba Menthae is independently lyophilized to obtain powder, and the other raw materials are extract concentrated solution obtained by boiling extraction, powder obtained by spray drying, and mixing with herba Menthae lyophilized powder.
4. The method for preparing a Chinese medicinal composition for relieving upper airway inflammation and controlling upper airway allergic reaction according to claim 1, which comprises the following steps:
5. The method of claim 4, wherein the step of preparing the composition comprises
The operation method comprises the following steps:
boiling and extracting;
the material-liquid ratio is 1: 10;
sieving for 60min, and discharging;
the time is 30min, and the materials are sieved and discharged.
6. The method for preparing a Chinese medicinal composition for relieving upper airway inflammation and controlling upper airway allergic reaction according to claim 4 or 5, wherein the steps are as follows
The optimization operation method comprises the following steps:
7. The use of the composition of claim 1 for the preparation of a medicament for the relief of upper airway inflammation and the control of upper airway allergic reactions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711013148.9A CN107744583B (en) | 2017-10-26 | 2017-10-26 | Traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway anaphylactic reaction, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711013148.9A CN107744583B (en) | 2017-10-26 | 2017-10-26 | Traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway anaphylactic reaction, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107744583A CN107744583A (en) | 2018-03-02 |
| CN107744583B true CN107744583B (en) | 2020-07-24 |
Family
ID=61254285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711013148.9A Active CN107744583B (en) | 2017-10-26 | 2017-10-26 | Traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway anaphylactic reaction, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107744583B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109675000A (en) * | 2019-01-23 | 2019-04-26 | 上海健顺生物科技有限公司 | A kind of draft is containing changing granular recipe and its preparation process |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106943583A (en) * | 2017-05-17 | 2017-07-14 | 贵州红润生物科技有限公司 | The luxuriant oral liquid of one kind plus-minus and preparation method |
| KR20170082957A (en) * | 2016-01-07 | 2017-07-17 | 랜기어 테크놀러지 씨오. 엘티디 | Medicine for treating nasal obstruction and cough |
-
2017
- 2017-10-26 CN CN201711013148.9A patent/CN107744583B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170082957A (en) * | 2016-01-07 | 2017-07-17 | 랜기어 테크놀러지 씨오. 엘티디 | Medicine for treating nasal obstruction and cough |
| CN106943583A (en) * | 2017-05-17 | 2017-07-14 | 贵州红润生物科技有限公司 | The luxuriant oral liquid of one kind plus-minus and preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 加减葳蕤汤治疗慢性咽炎;张伟斌;《四川中医》;19881231(第7期);第46页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107744583A (en) | 2018-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106138360A (en) | A kind of Chinese medicine composition and preparation method thereof, application | |
| CN107174638A (en) | A kind of cough-relieving medicinal extract and preparation method thereof | |
| CN114073730A (en) | Traditional Chinese medicine composition for preventing or treating air-conditioning syndrome | |
| CN101579186B (en) | Pharmaceutical rhinitis pillow for external use and treating wind-heat rhinitis | |
| CN108324833B (en) | Traditional Chinese medicine preparation for treating connective tissue disease-related interstitial lung disease | |
| CN101618146A (en) | Complex traditional Chinese medicine preparation for treating upper respiratory tract infection and preparation method thereof | |
| CN103961614B (en) | Chinese medicine composition for treating respiratory disease and its production and use | |
| CN107744583B (en) | Traditional Chinese medicine composition for relieving upper airway inflammation and controlling upper airway anaphylactic reaction, and preparation method and application thereof | |
| CN104983968B (en) | Antipyretic traditional Chinese medicine composition and preparation method thereof | |
| CN111840456A (en) | Chinese medicinal composition for treating respiratory system diseases | |
| CN104189819B (en) | A kind of Chinese medicine preparation for being used to nurse one's health emotional health | |
| CN102327525A (en) | Chinese medicinal composition for treating bronchiectasis | |
| CN105497723A (en) | Traditional Chinese medicine preparation for treating bacterial pneumonia and preparation method thereof | |
| CN105381310A (en) | Traditional Chinese medicine preparation for treating phthisis and preparing method thereof | |
| CN116139237A (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
| CN109106774B (en) | Traditional Chinese medicine composition for treating adenoidal hypertrophy and complications thereof, and preparation method and application thereof | |
| CN115486488A (en) | Tea drink composition for common food and application thereof | |
| CN1966051B (en) | Antivirus medicament for resisting virus | |
| CN104189605B (en) | Traditional Chinese preparation for treating acute nasopharyngitis and preparation method thereof | |
| CN106581620A (en) | Body resistance strengthening and cough relieving traditional Chinese medicine | |
| CN112168947A (en) | Traditional Chinese medicine composition for treating pneumonia and preparation method thereof | |
| CN107753664B (en) | Traditional Chinese medicine composition for treating allergic rhinitis and preparation method thereof | |
| CN110917271A (en) | Spray for preventing and treating allergic asthma combined allergic rhinitis of children and teenagers | |
| CN104173830A (en) | Medicament for reconciling interior syndromes and relieving exterior syndromes for high fever of cold in winter and preparation method thereof | |
| CN114470110B (en) | Anti-rhinitis traditional Chinese medicine composition with pain relieving effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |